HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $65
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $58 to $65.
Stocks · News reference
Liquidia Settles Bitter Fight With United Therapeutics
Liquidia (LQDA) stock jumped 40% after settling all lawsuit battles with United Therapeutics for $380.7M. YUTREPIA PAH sales continue.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq Dips Over 400 Points; Bank of America Shares Tumble After Q3 Results
US stocks fell Wednesday as Nasdaq dropped 1.54% and Dow 0.35%; Bank of America sank 5% after weak results, while oil rose and inflation topped forecasts.
Wells Fargo Maintains Equal-Weight on Liquidia, Raises Price Target to $33
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Equal-Weight and raises the price target from $30 to $33.
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
8-K filing — UNITED THERAPEUTICS Corp (UTHR)
Filed: 2026-10-14 AccNo: 0001104659-26-115723 Size: 417 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain Even as September Inflation Report Comes In Hotter Than Expected— ASML, AZZ, GME in Focus (UPDATED)
U.S. stock futures were higher on Wednesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Tuesday's lower close.